Your browser doesn't support javascript.
loading
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison, Maura L; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A Dimitrios; Licitra, Lisa; Harrington, Kevin J; Kasper, Stefan; Vokes, Everett E; Even, Caroline; Worden, Francis; Saba, Nabil F; Iglesias Docampo, Lara Carmen; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Monga, Manish; Lynch, Mark; Li, Li; Ferris, Robert L.
Afiliação
  • Gillison ML; MD Anderson Cancer Center, Houston, Texas, USA mgillison@mdanderson.org.
  • Blumenschein G; MD Anderson Cancer Center, Houston, Texas, USA.
  • Fayette J; Centre Leon Berard, Lyon, France.
  • Guigay J; Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice, France.
  • Colevas AD; Stanford University, Stanford, California, USA.
  • Licitra L; Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
  • Harrington KJ; Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, United Kingdom.
  • Kasper S; West German Cancer Center, University Hospital, Essen, Germany.
  • Vokes EE; University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
  • Even C; Gustave Roussy, Villejuif Cedex, France.
  • Worden F; University of Michigan, Ann Arbor, Michigan, USA.
  • Saba NF; Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Iglesias Docampo LC; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Haddad R; Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
  • Rordorf T; Universitätsspital Zurich, Zurich, Switzerland.
  • Kiyota N; Kobe University Hospital Cancer Center, Kobe, Japan.
  • Tahara M; National Cancer Center Hospital East, Kashiwa, Japan.
  • Monga M; Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • Lynch M; Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • Li L; Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • Ferris RL; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Oncologist ; 23(9): 1079-1082, 2018 09.
Article em En | MEDLINE | ID: mdl-29866947
ABSTRACT
Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Nivolumabe / Neoplasias de Cabeça e Pescoço Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Nivolumabe / Neoplasias de Cabeça e Pescoço Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos